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Serotonin 1A receptors (5-HT1A Rs) are implicated in the control of mood, cognition and 
memory. Dysfunction of 5-HT1A R signaling results in various neuropsychiatric disorders such 
as depression, anxiety and schizophrenia. Thus, 5-HT1A Rs are a good target for the treatment of 
the neuropsychiatric diseases.  
Previous studies have shown that 5-HT1A Rs can be SUMOylated by SUMO1 in rat brain 
areas such as cortex, hypothalamus and hippocampus. Studies have also shown that SUMOylated 
5-HT1A Rs cannot bind to agonist. In addition, it was reported that SUMOylation of 5-HT1A Rs 
in the hypothalamic membrane increased by treatment with the 5-HT1A R agonist (+)-8-
Hydroxy-2-dipropylaminotetralin ((+)8-OH-DPAT) and was further enhanced by combination of 
treatment of 17β-estradiol-3-benzoate (EB) and 8-OH-DPAT. Identifying the mechanism 
involved in SUMOylation of 5-HT1A Rs will be important for understanding the regulation of 5-
HT1A Rs, which will inform the development of novel therapeutic approaches to the 
neuropsychiatric diseases. Therefore, the purpose of this thesis is to investigate the mechanisms 
involved in SUMOylation of 5-HT1A Rs, specifically to determine whether PIAS proteins play a 
role in the SUMOylation of 5-HT1A Rs. I hypothesize that selective PIAS proteins increase 
SUMOylation of 5-HT1A Rs. 
In the first study, I developed a cell culture model to examine the SUMOylation of 5-
HT1A Rs. I found that mouse Neuroblastoma 2a (N2a) cells express endogenous 5-HT1A Rs and 
PIAS proteins. In addition, N2a cells can overexpress PIAS proteins and SENPs. The 
SUMOylation of 5-HT1A Rs was detected around 55 kDa in N2a cells similar to that reported in 
rat brain tissue. Transfected PIAS constructs expressed in the membrane and cytosol fractions of 
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N2a cells and various PIAS constructs showed different expression levels. PIASxα significantly 
increased the SUMOylated 5-HT1A Rs compared to other PIAS proteins. 
In the second study, I tested the hypothesis that the treatment of rats with 8-OH-DPAT 
and/or EB increased expression of PIASxα resulting in an increased level of SUMO 1-5-HT1A Rs. 
The results show an increase in the expression level of PIASxα in rats co-treated with EB and 8-
OH-DPAT compared to the expression level of PIASxα in either the EB treated or vehicle 
treated groups. Interestingly, the expression level of PIASy was increased in the rats treated with 
EB alone compared to vehicle treated rats.  
Together, these data suggest that PIASxα plays a role in increasing SUMOylation of 5-
HT1A Rs. Targeting PIASxα in the SUMOylation of 5-HT1A Rs could have important clinical 
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CHAPTER 1: INTRODUCTION 
1.1. Depression and Anti-depressants 
1.1.1. Depression 
Depression is a common mental disorder, characterized by sadness, loss of interest, 
feelings of guilt or worthlessness, insomnia, appetite loss, feelings of tiredness and poor 
concentration [2]. It affects over 350 million people worldwide. It is found to be more prominent 
in females than males and it typically initiates at a young age with a peak age of onset in the mid 
30’s [3]. The annual cost for patients diagnosed with major depression disorder (MDD) is $210.5 
billion in 2010 in US [4].   
There are several types of depressive disorders [2] .  
 Major depression: severe episodes of depression can occur only once or many 
times during a patient’s lifetime. 
 Persistent depressive disorder:  this type of depression lasts more than 2 years.  
 Psychotic depression: the patients feel depressed and also have some symptoms of 
psychosis, such as hallucinations.  
 Postpartum depression: 10 to 15 percent of women after giving birth feel 
overwhelmed with caring for the baby and with post-partum hormonal and physical changes, 
will experience postpartum depression.  
 Seasonal affective disorder (SAD): This type of depression occurs during winter 
when there is less sunlight.  
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 Bipolar disorder: Patients experience episodes of depression followed by mania. It 
is considered a separate disorder but includes the symptoms of depression.  
Several brain regions are involved in the pathophysiology of depression including 
cingulate cortex, nucleus accumbens, amygdala and hippocampus [5].  Some hypotheses for the 
etiology of depression have been proposed. One of the hypotheses for the underlying cause of 
depression is the monoaminergic hypothesis, which suggests depletion of monoamines (e.g. 
norepinephrine, dopamine and serotonin) or alterations in sensitivity of post-synaptic receptors 
(e.g. serotonergic receptors) in the central nervous system leads to depression [6]. Drugs like 
Selective Serotonin Reuptake Inhibitors (SSRIs) were developed based on this hypothesis [7]. 
Another hypothesis is that depression is related to the Brain-Derived Neurotrophic Factor 
(BDNF). BDNF is expressed most widely among the neurotrophin family in the mammalian 
brain. It participates in the cellular proliferation, migration, differentiation as well as regulation 
of  almost all the neuronal circuit development like neurogenesis, neuronal differentiation and 
neuronal polarization [8]. In the patients with depression, decreased expression of BDNF was 
found whereas antidepressants increased the expression level of BDNF and thus alleviated the 
symptoms [8-10].  
1.1.2. Anti-depressants  
Major antidepressants are classified into several types: monoamine oxidase inhibitors 
(MAOIs); tricyclic antidepressants (TCAs); selective serotonin reuptake inhibitors (SSRIs); 
serotonin and norepinephrine reuptake inhibitors (SNRIs); norepinephrine and dopamine 




Monoamine oxidase is involved in the serotonin degradation. Thus, MAOIs can reduce 
the degradation of serotonin, norepinephrine and dopamine. As a result, the amount release of 
these neurotransmitters increases. However, the side effects of MAOI such as low blood 
pressure, fatigue, lethal dietary and drug interactions result in MAOIs being the last line of 
treatment for depression.   
TCAs such as amitriptyline can inhibit serotonin, norepinephrine, and dopamine 
transporters, which subsequently can increase the neurotransmitters in the synaptic cleft. 
However, non-selectivity of TCAs leads to its greater side effects including cardiotoxicity. 
SSRIs like citalopram, escitalopram, fluoxetine and fluvoxamine are the most widely 
used anti-depressants. SSRIs are more selective and thus the side effects are less severe 
compared to MAOIs and TCAs. The serotonin transporter (SERT), present in the presynaptic 
terminals, cell bodies and dendrites of serotonergic neurons, is capable of transporting serotonin 
from the synaptic cleft back into the presynaptic neuron. It is thought that the SSRIs act through 
inhibiting serotonin re-uptake by SERT. 
SNRIs such as venlafaxine act on norepinephrine transporter (NET) and serotonin 
transporter (SERT), but they work more efficiently on SERT than NET. In comparison to SSRIs, 
they treat a wider range of symptoms than SSRIs and the side effects of SNRIs are more 
manageable than SSRIs. However, the beneficial effects of SNRIs vary between patients.  
The only NDRIs approved by FDA for clinical use is bupropion. As an atypical 
antidepressant, bupropion serves as an add-on medication with SSRIs. However, bupropion was 




The direct actions of the anti-depressants are known. However, the mechanisms by which 
they improve depression have not been elucidated clearly. For example, the SSRIs can inhibit the 
SERT resulting in serotonin remaining in the synaptic cleft for a prolonged timed. However, the 
inhibition of reuptake of serotonin occurs very rapidly [11] and it usually takes an average 6–7 
weeks for SSRIs to produce the anti-depressant effects. This lag in therapeutic response suggests 
that adaptive changes such as serotonin receptor desensitization (based on the monoamine 
hypothesis) and neuronal proliferation (based on the BDNF hypothesis) likely contribute to the 
therapeutic response. Thus, it is important to develop a novel therapy for SSRIs to reduce the 
therapeutic lag. Therefore, it is imperative to explore more about the adaptive mechanisms. 
Furthermore, more efficacious drugs are needed, considering only about 1/3 of patients 
experience relief from current medications [12].  
1.2. Serotonin  
Serotonin is a monoamine neurotransmitter, the dysregulation of which can lead to 
alterations of mood, anxiety, pain disorders and psychosis. Serotonin is distributed in central 
nervous system, enterochromaffin cells and blood platelets [13]. There are 14 known human 
serotonin receptors including 5-HT 1A, 1B, 1D, 1E, 1F, 2A, 2B, 2C, 3, 4, 5A, 5B, 6, 7. 5-HT 3 
receptor is the only ionotropic receptor while the others are G protein coupled receptors 
(GPCRs). Different serotonin receptors can locate in the same cells [13].  
1.2.1. Serotonin 1A Receptors 
1.2.2.1. Structure, distribution and signaling 
Serotonin 1A receptors (5-HT1A Rs) bind to serotonin with high affinity and play an 
important role in the regulation of emotion. 5-HT1A Rs contain 422 amino acids, with a predicted 
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molecular weight around 42 kDa. The identity between the sequence of 5-HT1A Rs in rats and in 
human is 89%. 5-HT1A Rs belong to the super family of GPCRs, which are expressed on the 
plasma membrane and possess seven membrane-spanning domains. For the GPCRs, the C-
terminus is usually involved in the post-translational modifications. 
5-HT1A Rs are located in the both pre-synaptic and post-synaptic membrane of neurons. 
Presynaptic 5-HT1A receptors are exclusively present in the 5-HT neurons with cell bodies 
located in raphe nuclei (both dorsal and median) [14-16], where central serotonergic neurons are 
located, mediating feedback regulation of 5-HT release. The activation of these pre-synaptic 
receptors causes a suppression of 5-HT synthesis. Postsynaptic 5-HT1A receptors are located in 
the cortico-limbic regions, including the cortex (particularly prefrontal and enthorinal cortex), 
hippocampus, septum, amygdala as well as the hypothalamus [17]. The postsynaptic 5-HT1A 
receptors receive serotonergic innervation from the raphe nuclei and in this way, the presynaptic 
5-HT1A receptors in serotonergic neurons can regulate the serotonergic activity in projection 
areas. In terms of cellular location, the expression of 5-HT1A Rs was observed in the dendrites 
and soma of glutamatergic pyramidal neurons, axon terminals of GABAergic and cholinergic 
neurons [17] as well as in the non-neuronal cells like astrocytes [18].  
5-HT1A Rs couple to Gαi/Gαo (Go, Gαi1/2/3), resulting in decreased level of cAMP, 
mediating inhibitory neurotransmission. 5-HT1A Rs couple to Gαi3 exclusively in the anterior 
raphe. 5-HT1A Rs couple to Gαi3 and Gαo equally in the cerebral cortex and preferentially to Gαo 
compared to Gαi3 in the hippocampus.  In the hypothalamus, in addition to coupling to Gαi/o, 5-




5-HT1A Rs modulate serotonergic sensitivity and the imbalance of 5-HT1A Rs in cortico-
limbic regions, might affect the emotional state of an individual [20, 21], and impacts cognition, 
anxiety and depression. 5-HT1A Rs can affect neuronal development and  synapse formation [22]. 
It was shown that 5-HT1A Rs receptor-deficient animals exhibited the anxiety-related behaviors 
[23-25] such as reduced exploration of the central area in the open field test [24]. The 5-HT1A Rs 
knockout mice showed a decreased immobility in the forced swim test, a test for antidepressants 
[23]. It was also shown that the SSRI - fluoxetine elevated serotonin levels in 5-HT1A–/– mice 
and wild type mice, but the level of serotonin increased more dramatically in  5-HT1A–/– mice 
[26-28]. Taken together, these observations establish the significance of 5-HT1A Rs in depression 
and anxiety. 
1.2.2.3. Desensitization of 5-HT1A Rs  
SSRIs bind serotonin transporter (SERT) and block the reuptake of serotonin (5-HT), 
which results in an increased level of 5-HT in the synapse. 5-HT1A auto-receptors are then 
stimulated and mediate feedback regulation of 5-HT release, which leads to the down-regulation 
of 5-HT in the synapse and then the up-regulation of post-synaptic 5-HT1A Rs. 5-HT1AR agonists 
can also activate the 5-HT1A auto-receptors and result in the same condition. However, with 
long-term exposure to 5-HT or activation of 5-HT1A Rs, the auto-receptors become desensitized, 
leading to the increased release of 5-HT, which leads to desensitization of the post-synaptic 5-
HT1A receptors. Collectively, the prolonged 5-HT binding to the 5-HT1A Rs causes desensitization 
and reduces the level of hyperpolarization [29]. 
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Long-term administration of SSRIs also causes desensitization of post-synaptic 5-HT1A 
Rs in the hypothalamic paraventricular nucleus (PVN) [30-32], which regulates the release of 
oxytocin and adrenocorticotropic hormone (ACTH). Long-term administration of SSRIs leads to 
reductions in 5-HT1A R-stimulated release of oxytocin and ACTH as well as ACTH-stimulated 
release of cortisol. The hyper-responsivness of hypothalamic-Pituitary-Adrenal (HPA) Axis, 
which controls the release of ACTH and cortisol, is the consistent biomarker for depressed 
patients [33, 34]. The normalization of HPA axis function is correlated to the remission of 
depression. Based on these findings, we hypothesize that desensitization of 5-HT1A Rs in PVN 
contributes to the therapeutic effects of SSRIs and is a critical step in treating depressed patients 
with SSRIs. If desensitization of 5-HT1A receptor signaling contributes to the efficacy of anti-
depressants, promoting desensitization of 5-HT1A Rs may shorten the therapeutic lag time [29, 
35].   
Estrogens such as estradiol were shown to accelerate the desensitization of 5-HT1A Rs in 
the PVN [29, 36]. Our previous studies have shown that administration of estradiol for 2 days 
results in the reduced ACTH or oxytocin responses to 5-HT1A Rs agonist, 8-OH-DPAT. 
Estradiol treatment causes a partial desensitization of 5-HT1A Rs, whereas treatment with 
fluoxetine (SSRI) for 7 days or combination of fluoxetine and estradiol for 2 days caused a full 
desensitization of 5-HT1A Rs [29].   
However the mechanisms involved in the desensitization of 5-HT1A Rs by estradiol are 
not clear. Previous studies in the laboratory demonstrated that 5-HT1A Rs can be SUMOylated, 
treatment with an agonist 8-OH-DPAT increased SUMOylation of the receptors and treatment 
with estradiol for 2 days further increased the 8-OH-DPAT-induced SUMOylation of 5-HT1A Rs 
in the PVN [35]. Since the administration of estradiol for 2 days induced the desensitization of 5-
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HT1A Rs, we hypothesize that SUMOylation could contribute to the desensitization of the 5-
HT1A Rs. Thus, it is important to understand role of SUMOylation in regulation of 5-HT1A R and 
the mechanisms involved in the SUMOylation of 5-HT1A Rs.   
1.3. SUMOylation  
1.3.1. Small Ubiquitin-like Modifier (SUMO) proteins 
SUMO proteins are ubiquitin-like polypeptides that can be covalently conjugated to 
cellular proteins in a manner similar to ubiquitylation.  There are 4 isoforms of SUMO confirmed 
in humans: SUMO 1, SUMO 2, SUMO 3 and SUMO 4. There exists a high degree of similarity 
between SUMO 2 and SUMO 3, only differing in three residues in the N-terminus [37]. The 
identity of SUMO 2 and SUMO3 makes them difficult to differentiate; they are usually referred 
to as SUMO 2/3. The similarity between SUMO 1 and SUMO 2/3 is around 45%. In addition, 
the subcellular distribution of SUMO 1 and SUMO 2/3 is also different. SUMO 2/3 is distributed 
throughout the nucleoplasm while SUMO 1 is located at the nuclear envelope and the nucleolus. 
There is a large amount of unconjugated SUMO 2/3 compared to SUMO 1 in cells [38]. 
Moreover, under various stressors, the SUMO 2/3 conjugation to substrates can be strongly 
enhanced whereas that of SUMO 1 cannot. Interestingly, SUMO 2/3 can be SUMOylated at Lys 
residues by chains of SUMO 2/3 proteins and terminated by SUMO 1, thereby resulting in the 
formation of poly-SUMOylation [39, 40]. Some substrates can be SUMOylated by multiple 
SUMO proteins at different sites on the substrates [41]. Poly-SUMOylation might create a 




The identity between SUMO 2/3 and SUMO 4 is also high but there is a proline instead 
of glutamine at position 90 in SUMO 4. Native SUMO 4 can only become mature and able to 
conjugate to substrates under stressful conditions [43]. Another difference of SUMO 4 to the 
other SUMO proteins is the distribution. SUMO 4 mRNA has been only found in the kidneys, 
dendritic cells and macrophages while SUMO 1, SUMO 2, and SUMO 3 exist universally in all 
tissues in humans [37, 44].  However, the function of SUMO 4 is only understood to a limited 
degree. 
1.3.2. Mechanism involved in SUMOylation  
A comparison of sequences of the SUMO-modified proteins at the SUMOylation sites 
indicated that most sites contain the consensus motif Ψ-K-x-D/E (Ψ: hydrophobic residue 
consisting of 3–4 aliphatic residues, K: lysine conjugated to SUMO, x: any amino acid (aa), D/E: 
an acidic residue) [45]. The hydrophobic residue is quintessential for SUMOylation consensus 
motif. The preference of protein to SUMO isoforms might depend on the arrangement of 
hydrophobic and acidic residues in SUMOylation consensus motif [46]. The protein interaction 
with SUMO 1 but not with SUMO-2 can be attributed to the clusters of negatively charged 
amino acids at the C terminus to the hydrophobic core. SUMO 2/3 possesses Ψ-K-x-D/E 
sequences in their N-terminal extensions, which can explain why the SUMO2/3 can form the 
poly-SUMO chains [40]. In S. cerevisiae, there are three lysine residues (K11, K15 and K19) 
that are known SUMOylation sites at N-terminus of Smt3p, while in mammals, only one lysine 
residue (K11) of SUMO 2/3 is identified as a SUMOylation consensus site [42]. SUMO proteins 
can also bind to other proteins non-covalently through the SUMO-interaction motif (SIM). For 
example, one type of SUMO E3 ligase - PIAS proteins contain a SIM, allowing PIAS proteins to 
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interact with SUMO proteins non-covalently. Consensus sites for SIMs have been identified. 
However, there is little similarity between the SIMs.  
SUMO proteins are conjugated to their substrates via an isopeptide bond linkage between 
the di-glycines at C terminus of SUMO and a lysine residue in the substrate. In mammals, the 
process of SUMOylation contains three steps. First, the SUMO precursor becomes mature 
SUMO through cleavage to expose glycine-glycine at the C-terminal by the SUMO-specific 
proteases (SENPs). Second, the mature SUMO is activated by an E1 activating enzyme which is 
a complex, formed by a heterodimer of SAE1and SAE2, and forming a thioester bond in an 
ATP-dependent manner. Third, the activated SUMO is then transferred from the E1 activating 
enzyme to E2 conjugating enzyme - ubiquitin carrier protein 9 (Ubc9), forming the thioester 
conjugate again. Subsequently, the SUMO protein is passed from Ubc9 to the substrate with a 
lysine residue (K) via an isopeptide bond. However, there are some substrates that require E3 
ligases for the modification by SUMO [1]. Several SUMO E3 ligases (Table 1) act as an adapter 
between E2 enzyme and the substrates, transferring SUMO from Ubc9 to substrates, accelerating 
SUMOylation of substrates. Ultimately, deSUMOylating enzymes with isopeptidase activity 
remove SUMO from SUMO-modified proteins. In this way, SUMOylation and deSUMOylation 
processes provide a regulatory mechanism to tightly control the SUMO-modification of 





SUMOylation is frequently associated with modulating DNA transcription. The SUMO 
signaling pathway is also involved in regulating mitochondrial function and morphology [49], 
cellular stress as well as cellular senescence and ageing [50]. Furthermore, SUMOylation can 
modulate synapse formation, spine morphogenesis, neurotransmission and synaptic plasticity and 
thus plays an important role in neurodegenerative diseases [51]. For example, SUMOylation of 
mutant Huntington protein is toxic in Huntington’s disease [52]. Tau possesses two SIMs and 
can be SUMOylated at K340, which might affect the pathology of Alzheimer’s disease [53]. 
1.3.3. SUMOylation Machinery 




Figure 1. The mechanism of SUMOylation signaling pathway 
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E1 Activating enzymes 
All the cellular SUMO E1 enzymes are found as heterodimers across species. In 
mammalian cells, SUMO E1 enzymes consist of SAE1 and SAE2, unlike the ubiquitin E1 
activating enzymes (Ub E1s) which exist as a monomer. However, the structure of SUMO E1 
enzymes is similar to Ub E1s. Specifically, in the Saccharomyces cerevisiae, Aos1p (40 kDa) 
resembles the N-terminus of Ub E1s, while Uba2p (71 kDa) corresponds to the C-terminus of Ub 
E1s and contains the active site of cysteine [54-58]. In mammals, the active site cysteine is 
Table 1. The enzymes involved in the SUMOylation including Small ubiquitin-related 
modifiers, E1 activating enzymes, E2 conjugating enzymes, E3 ligases and 
deSUMOylation proteases in the mammals, S.cerevidise, and S.pombe [1].  
Table 1 The enzymes involved in the SUMOylation  
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located at Cys-173 [56]. The thiol in the active site cysteine in SUMO E1s conjugates to the C 
terminus of SUMO and forms a thioester bond [56]. SAE1 and SAE2 are localized in the nucleus 
[59] and cytoplasm [60]. 
E2 Conjugating enzyme 
There is only one E2 conjugating enzyme for SUMOylation – Ubc9 in yeast, 
invertebrates and possibly in the vertebrates [61-64], unlike ubiquitin E2 enzymes which 
contains multiple proteins participating in the ubiquitin pathway. But Ubc9 is homologous to 
ubiquitin E2 enzymes. Human Ubc9 is a 17kDa protein[37]. It is distributed throughout the 
mammalian cells, including the cytoplasm, nucleus, nuclear pore complex, around the nuclear 
envelope and the cell membrane [37, 65]. Ubc9 can recognize and catalyze the attachment of 
SUMO proteins to specific substrates. However, the ability of Ubc9 to bind to substrates is 
comparatively weak. Thus, SUMOylation does not occur for most substrates without SUMO E3 
ligases [51].  
SUMO E3 ligases 
SUMO E3 ligases facilitate the conjugation of most substrates  to SUMO under 
physiological conditions [66]. SUMO E3 ligases that have been identified include (Siz/PIAS 
RING) SP-RING-type E3 ligases, IR E3 ligase which contains two internal repeat (IR) domains 
and other potential SUMO ligases. 
SP-RING-type E3 ligases 
The SP-RING-type E3 ligases contain Siz/PIAS RING-finger-like domains (SP-RING 
domains). In the yeast, SUMO E3 ligases are comprised of Siz1, Siz2, Zip3p and Mms21p. The 
majority of conjugation of SUMO to substrates in the yeast require E3 ligases [67, 68]. In the 
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mammalian cells, the SP-RING-type E3 ligases include 5 types of the protein inhibitor activated 
STAT (PIAS) family, consisting of PIAS1, PIASxα, PIASxβ, PIAS3 and PIASy. They contain 
around 600 amino acid residues. PIAS1 and PIAS3 were first discovered as inhibitors of signal 
transducer and activator of transcription-1 (STAT1) and -3 (STAT3) and acted by blocking 
STAT binding to DNA in the nucleus [69-71]. In contrast, PIASy proteins inhibit the activity of 
STAT1 without affecting its binding. Both PIASxα and PIASxβ can repress the activity of 
STAT4. Later, PIAS proteins were found to function as SUMO ligases as they can enhance the 
interaction of SUMO with other proteins including androgen receptor (AR), p53 and 
glucocorticoid receptors [72-74].  Another SP-RING-type E3 ligase is Mms21, first was found as 
the SUMO ligase in the yeast and later was demonstrated to be a SUMO E3 ligase as well in 
humans [75]. Mms21 was shown to prevent apoptosis induced by prevention of DNA damage in 
human cells [75].  
Among the 5 types of mammalian PIAS proteins, there is high similarity of amino acid 
sequence.  The most conserved regions are the first 60 amino acids at the N terminus and the 
central region which is rich in cysteine residues. Five domains (Figure 2) [76] have been 
identified in PIAS proteins with different functions: an N-terminal scaffold attachment factor-
A/B/acinus/PIAS (SAP) motif for direct-DNA binding or interaction with other proteins related 
to DNA-binding [77], the PINIT motif predicted for protein localization [78], the RING-type 
zinc-binding structure domain that is abundant with cysteine residues called Siz/PIAS RING(SP-
RING) essential for the E3 SUMO-ligase activity [79], the SIM acting in interaction with SUMO 
proteins non-covalently [80], and the C-terminal serine/threonine rich region (S/T) with the least 
conserved sequences. There are two isoforms for PIASx - PIASxα and PIASxβ [76]. The domain 
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PIAS1, PIASxα, PIASxβ, PIAS3, PIASy are reported to localize in nucleus and 
cytoplasm. However, the subcellular distribution of these proteins has not been clearly identified. 
In addition, the localization of other SUMOylation machinery is not completely explored as well. 
To date, SUMOylation has been considered to occur primarily in the nucleus. However, recently, 
it was reported that in cultured neurons, SUMO machinery including SUMO proteins, the E1 
enzymes, E2 enzymes, E3 ligases and SENPs, are not only located in the nucleus, but also in 
neuronal axons and dendrites as well as synapses. Moreover, these proteins traffic to different 
regions of neurons during neuronal development [82-85]. These results indicate that the 
SUMOylation machinery in neurons is dynamic during neuronal development. However, the 
mechanism underlying trafficking is unclear. For the Siz1, one of the Siz/PIAS RING family of 
SUMO E3 ligases in the S. cerevisiae, the nuclear localization might be related to the SAP 
Figure 2. The structure of PIAS Proteins. The PIAS Proteins contains 5 domains including 
an N-terminal scaffold attachment factor-A/B/acinus/PIAS (SAP) motif, the PINIT motif, 
Siz/PIAS RING (SP-RING) domain, SUMO binding motif (SIM) and the C-terminal 
serine/threonine rich region (S/T) domain. 
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domain. Siz1 with a deletion of SAP from bp 139 to 180 decreased nuclear localization to some 
extent [86, 87]. C-terminal domain of Siz1 is necessary for the distribution of Siz1 to the bud 
neck. More studies need to be conducted to understand the regulation of  the localization of E3 
ligases [87, 88]. 
Different PIAS proteins have preferences for different substrates. In addition, PIAS 
proteins have selectivity to different SUMO proteins. For example, PIASxα was capable of 
facilitating the interaction between SUMO1 and the tumor suppressor PTEN more than the other 
PIAS proteins [89]. PIASxβ acts as the ligase for SUMO1 conjugation to protein kinase C-θ 
(PKC-θ) in T cells [90], consequently influencing T cell activation. PIAS1, PIAS3 and PIASy 
interact with p53 and c-jun proto-oncogenes and repress the activity of the p53 tumor suppressor 
protein [91, 92]. Gocke et al., also reported that PIAS1 and PIASxβ can facilitate SUMOylation 
of a broader range of substrates than PIASy [93]. In terms of selectivity for SUMO proteins, 
PIASy prefers to facilitate the modification of lymphoid enhancer factor 1 (LEF1) by SUMO 2, 
but not SUMO 1, even though LEF1 can be modified by both SUMO 1 and SUMO 2 [94]. 
GATA-2 can be SUMOylated by SUMO 1 and SUMO 2, but PIASy prefers to enhance the 
conjugation of SUMO2 to GATA-2 [95].  
The mechanism by which PIAS proteins facilitate the conjugation of different SUMO 
proteins to different substrates was elucidated to some extent in terms of structure. Yunus et al., 
used Siz1 to study the mechanism involved in the binding to SUMO machinery and substrates. 
They found the SP-CTD domain (a C-terminal domain) binds to SUMO protein, the SP-RING 
domain binds to Ubc9 and N-terminal PINIT domain attached to the substrate - the proliferating 
cell nuclear antigen (PCNA) at lysine 164, a non-consensus SUMO site [96]. They also found 
that E3 ligases can activate the E2~SUMO thioester [96]. This provides the information to 
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understand how the SUMO E3 ligases facilitate the SUMOylation and select both SUMO and 
substrates. This information can be used with other substrates in which E3 ligase plays an 
important role for SUMO modification.  
IR type E3 ligase 
 There is only one IR type E3 ligase identified to date– RAN binding protein 2 (RanBP2). 
It is a member of nucleoporin family, and is around 358 kDa. RanBP2 contains an internal repeat 
(IR) domain, where around 50 residues are repeated twice (IR1 and IR2). Between the two 
repeated residues, there is a domain (M) consisting of 24 residues. Both the IR domains are 
responsible for the SUMO E3 ligase activity [97] . RanBP2 binds to the E2 enzyme and SUMO, 
changing the configuration and position of E2~SUMO complex, and thus facilitates the 
SUMOylation of substrates with enhanced the E2 activity [98]. 
Other SUMO E3 ligases 
There are 4 other potential SUMO E3 ligases, including Histone deacetylase 4 (HDAC4), 
Pc2, KRAB-associated protein 1 (KPA1) and Topors. 
HDAC4 itself is a SUMOylation substrate and also can augment the conjugation of 
SUMO to other proteins such as myocyte-specific enhancer factor 2 (MEF2) and LXRβ [99-
101]. The evidence that HDAC4 binds to E2 enzyme also suggests that HDAC4 is analogous to 
the SUMO E3 ligase [102].  
Pc2 is Polycomb group (PcG) protein. Pc2 can bind to the E2 enzyme. The SUMOylation 
of transcriptional co-repressor CtBP was enhanced by overexpression of  Pc2, which can recruit 
the CtBP to PcG bodies [103, 104].  
18 
 
The human co-repressor KRAB-associated protein 1 (KAP1) contains Plant 
homeodomain (PHD) fingers and bromodomains. It was found that PHD domains in KAP1 can 
catalyze the intramolecular SUMOylation of the adjacent KAP1 bromodomains [105, 106].  
Topors is a cellular RING finger protein, possessing a SIM domain which can interact 
with SUMO 1 or SUMO 2. It was shown that Topors enhanced the conjugation of SUMO 1 to 
p53 in vivo [107, 108]. 
1.3.3.2. The SUMO De-conjugation System 
In mammals, there are 9 types of SUMO proteases including 6 types of sentrin-specific 
proteases (SENPs) (SENP1, 2, 3, 5, 6 and 7), 2 types of deSUMOylating isopeptidases (DESl1 
and DESl2), and ubiquitin-specific protease-like 1 (USPL1). Some SUMO proteases can process 
the full-length SUMO proteins to become mature by exposing double glycine at C-terminal and 
de-conjugate SUMO proteins from substrates. The detailed information about the isoforms of 
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chains 
SENP7 SUMO 2/3 
chains 
Nucleoplasm No Yes, SUMO2/3 
chains 





DESl2 unknown Nucleus and 
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1.4. SUMOylation of G Protein coupled receptors (GPCRs) 
To date, there are only four GPCRs that are identified as the substrates for SUMOylation, 
including metabotropic glutamate receptors (mGluRs), a type of glutamate receptor. There are 8 
subtypes (mGluR1–8) in the family of mGluRs. It was reported that metabotropic glutamate 
Table 2. The characteristics of SUMO proteases in mammals 
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receptor 8b C-terminus has affinity for Pias1 and Pias3L in vitro. Pias1 enhanced the 
SUMOylation of mGluR8b at K882 and K903 in HEK 293 cells [110, 111]. 
mGluR7, a presynaptic GPCR, was also studied to examine whether it is indeed the 
substrate for SUMOylation. mGluR7 was found to interact with SUMO1 and SUMO2 in vitro, 
and SUMOylation was abolished by mutation of the receptor at lysine 889 [112]. Recently, Choi 
et al., demonstrated that mGluR7 can be SUMOylated at Lys889 both in brain and primary 
cortical neurons. L-AP4, an mGluR7 agonist and SENP1 reduced the SUMOylation of mGluR7. 
They also found that SENP 1 promotes the internalization of mGluR7, which indicates that 
deSUMOylation stimulates the internalization of mGluR7 [113]. 
The third GPCR that is known to be SUMOylated is cannabinoid receptor 1 (CB1). 
Gowran et al., found that SUMOylated CB1 was observed in control neurons while there is no 
detectable SUMO-CB1 in neurons treated with △9-tetrahydrocannabinol (△9-THC), the CB1 
agonist, which suggests that △9-THC induces the deSUMOylation of CB1 [114]. 
1.4.1. SUMOylation of 5-HT1A Rs 
Research [35] in our laboratory, demonstrated that 5-HT1A Rs can be SUMOylated. 
Studies showed that SUMO 1 conjugated to 5-HT1A Rs in the membrane fraction but not 
cytosolic fraction of rat cortex, resulting in a protein band around 55kD on western blots. The 
SUMOylated 5-HT1A Rs were not only detected in the cortex, but also observed abundantly in 
hypothalamus, amygdala, hippocampus, dorsal raphe but less SUMO 1-5-HT1A Rs in midbrain. 
In terms of the subcellular distribution, active 5-HT1A Rs are located in the detergent-resistant 
microdomain (DRM), while just small portion of SUMO 1-5-HT1A Rs were observed to be co-
localized with flotillin-1, a DRM marker. SUMO 1-5-HT1A Rs predominantly co-localized with 
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TGN38, a marker for trans-Golgi network (TGN), and calreticulin, a marker for the endoplasmic 
reticulum (ER). In order to determine whether the SUMO 1-5-HT1A Rs are functional, Li et al., 
used 8-OH-DPAT, a 5-HT1A R agonist, in an agonist binding assay. They found that the 
distribution of 5-HT1A Rs that bound 8-OH-DPAT did not overlap with the SUMO 1-5-HT1A Rs. 
These results suggests that SUMO1-5-HT1A Rs have low affinity to the 5-HT1A Rs agonist [35]. 
Taken together, these results suggest that SUMO 1-5-HT1A Rs are not active receptors. Based 
on these results, we speculate that after SUMOylation, 5-HT1A Rs may traffic from the DRM to 
the ER and TGN.  
Previous studies [35] also showed that the SUMOylated 5-HT1A Rs were increased in the 
hypothalamic membrane fraction and DRM of cortex of rats following the treatment with 8-OH-
DPAT for 15 min compared with the rats treated with saline. Moreover, administration of 
estradiol for 2 days can increase the 8-OH-DPAT-induced SUMOylated 5-HT1A Rs. Taken 
together, these results suggest that SUMOylation inactivates the 5-HT1A Rs, which may possibly 
accelerate the internalization or desensitization of 5-HT1A Rs in response to agonist stimulation. 
1.5. Statement of Purpose 
Depression is a common mental disorder, affecting over 350 million people worldwide. 
Although the mechanisms causing depression have been extensively studied and there are many 
types of anti-depressants on the market, there is still no effective cure for depression. Only 30-
40% of patients can be effectively treated with the current medications [12] and the response 
time to anti-depressants usually last an average 6-7 weeks [12, 115]. SSRIs inhibit SERT activity 
and thus increase the level of 5-HT in the synapse. Increased level of 5-HT in the synapse for a 
prolonged time desensitizes both pre-synaptic and post-synaptic 5-HT1A Rs in PVN [29, 31, 
116]. Considering that chronic treatment of SSRIs decreased the sensitivity of 5-HT1A Rs, we 
22 
 
hypothesize that desensitization of 5-HT1A receptor signaling may contribute to the delay of 
therapeutic effects of SSRIs. Previous work in our laboratory showed that 5-HT1A Rs can be 
SUMOylated and are predominantly located in the endoplasmic reticulum and golgi. Based on 
this, we hypothesized that SUMOylation of 5-HT1A Rs may be related to desensitization of 5-
HT1A Rs. We also reported that SUMOylation of 5-HT1A Rs were up-regulated by acute 
treatment with a 5-HT1A receptor agonist, 8-OH-DPAT. In addition, SUMO 1- 5-HT1A Rs 
increased more when rats were treated with estradiol prior to injection of 8-OH-DPAT, 
suggesting that 8-OH-DPAT and estradiol can accelerate SUMOylation of 5-HT1A Rs. However, 
the mechanism underlying the SUMOylation of 5-HT1A Rs is not clear. Specifically, the 
mechanism underlying the increase of SUMO1-5-HT1A Rs by 8-OH-DPAT or the increase of 8-
OH-DPAT-induced SUMO1-5-HT1A Rs by estradiol are still unknown. Exploring the 
mechanism involved in SUMOylation of 5-HT1A Rs will improve our understanding of 
desensitization of 5-HT1A receptors, and inform the development of an adjunct therapy to reduce 
the therapeutic lag of SSRIs. 
Therefore, the purpose of this study is to determine (1) the mechanism responsible for 
SUMOylation of 5-HT1A Rs and (2) the mechanism responsible for 8-OH-DPAT-induced 
SUMO1-5-HT1A Rs and the increase of 8-OH-DPAT-induced SUMO1-5-HT1A Rs by estradiol. 
To date, there are only four GPCRs reported to be the substrates of SUMO proteins. 
mGluR 8b was reported to interact with PIAS 1 and PIAS3L in vitro. The SUMOylation of 
mGluR8b was enhanced by PIAS1 in HEK 293 cells [110, 111]. Thus, we proposed the 




To test this hypothesis, we first set up a cell model for the detection of SUMOylation of 
5-HT1A Rs. We examined the expression of 5-HT1A Rs and the SUMOylation machinery 
including SUMO proteins, Ubc9 and PIAS proteins in a mouse neuroblastoma 2a (N2a) cells.  
Further, we transfected N2a cells with plasmid constructs of 5-HT1A receptors and SUMO1 to 
detect the expression of SUMO 1- 5-HT1A Rs in N2a cells. Next, we transfected N2a cells with 
plasmid constructs of different members of PIAS family to determine the effects of different 
PIAS proteins on SUMO 1- 5-HT1A Rs. 
Based on the results that 8-OH-DPAT increased SUMO 1- 5-HT1A Rs and estradiol 
accelerated 8-OH-DPAT-induced SUMO 1- 5-HT1A Rs, we asked the question whether PIAS 
proteins increase in the PVN membrane fraction and participate in the SUMOylation of 5-
HT1A Rs following the treatment by 8-OH-DPAT or co-treatment of estradiol and 8-OH-DPAT.  
 To answer this question, we proposed our second hypothesis that treatment of the 5-
HT1A receptor agonist and estradiol can enhance the expression of specific PIAS proteins in 
the membrane fraction of PVN in hypothalamus. 
To test this hypothesis, we used the PVN of the rats treated with 8-OH-DPAT and 
combined treatment with 8-OH-DPAT and estradiol to examine the expression levels of specific 








CHAPTER 2: MATERIALS AND METHODS 
2.1. Plasmid constructs 
The plasmid constructs used in the experiments are listed in Table 3. For plasmid 
isolation and purification, a QIAGEN®Plasmid Midi Kit (25) (Cat#12143, QIAGEN, USA) was 
used.  
            Table 3. Summary of the plasmid constructs used 
Plasmid constructs Vector Tag Source 
pcDNA4 HisMax C- 
5-HT1A Receptor 
pcDNA4 HisMax C His  
SRa-HA-SUMO 1 pcDNA3/HA HA Addgene, Plasmid# 
17359 
Flag-mPIAS1 pFLAG-CMV-(3800bp) Flag Plasmid# 15206, 
Addgene 
Flag-hPIASx alpha pFLAG-CMV-(3800bp) Flag Plasmid# 15209, 
Addgene 
Flag-hPIASx beta pFLAG-CMV-(3800bp) Flag Plasmid# 15210, 
Addgene 
Flag-mPIAS3 pFLAG-CMV-(3800bp) Flag Plasmid# 15207, 
Addgene 
Flag-hPIASy pFLAG-CMV(3800bp) Flag Plasmid# 15208, 
Addgene 




Flag-SENP2 pFLAG-CMV(4700bp) Flag Plasmid# 18047, 
Addgene 
Flag-SENP6 pFLAG-CMV(4700bp) Flag Plasmid# 18065, 
Addgene 
 
2.2. Cell culture and harvesting 
Mouse Neuroblastoma 2a cells (N2a cells) were maintained in 50% Dulbecco's Modified 
Eagle Medium (1X DMEM, high glucose, pyruvate, Cat# 11995-073, Thermo Fisher, USA) and 
50% Opti MEM (Cat# 31985088, Thermo Fisher, USA) supplemented with  10% Fetal Bovine 
Serum (FBS) (Cat# S11150, Atlanta Biologicals, USA ) and 1% Penicillin-Streptomycin solution 
(Cat# P0781-100ML, Sigma, USA). For transfection assays, N2a cells were plated in 10cm dish 
at a density of 2.2 x 10
6
 per dish. After 16-24 hours, cells were transfected with the mammalian 
expression plasmids constructs using Lipofectamine 3000 (Cat# L3000015, Thermo Fisher, 
USA). Medium was changed 6 hours and 24 hours after transfection.  
48 hours after transfection, cells were washed with phosphate-buffered saline and 
hypotonic buffer (0.25M sucrose 50 mM Tris, pH 7.5, 5mM EDTA, 100 mM NaCl. 20mM NEM 
was added before use). The cells were harvested with hypotonic buffer (20mM NEM, 1/100 
dilution of phosphatase inhibitors and protease inhibitors were added before use). After 
sonication, the homogenate was transferred to a centrifuge tube and spun at 25,000xg (16,500 
rpm) for 1 hr at 4
0
C. The supernatant was collected as cytosol fraction.  
The pellet was reconstituted with solubolization buffer (20 mM Tris, pH 8, 1 mM EDTA, 
100 mM NaCl. 1% sodium cholate, 20mM NEM, 1/100 dilution of phosphatase inhibitors and 
protease inhibitors were added before use). After sonication, the vials were shaken horizontally 
at high speed, at 4
o





1 hour. Supernatant was collected as the membrane fraction.  The solution was then aliquoted 
and stored in -80
o
C. BCA assay (Cat# 23228, Cat# 1859078, BCA Protein Assay, Thermo 
Fisher, USA) was used to measure the concentration of protein.  
2.3. Treatment of rats and preparation of membrane fraction of rats PVN  
The PVN tissue from rats used in this study was from rats used in a previously published 
study to determine the effects of 17β-estradiol-3-benzoate (EB) on oxytocin and ACTH 
responses [117]. The rats were treated with drugs as described below. EB was purchased from 
Sigma-Aldrich (St. Louis, MO). EB was first dissolved in 100% ethanol to a concentration of 
25μg/ml and then diluted to the final concentration with sesame oil. The EB solution and sesame 
oil were administered at 0.4ml/kg (EB dose 10μg/kg subcutaneous (s.c.)). (+)8-Hydroxy-2-
dipropylaminotetralin ((+)8-OH-DPAT) was purchased from Tocris (Ellisville, MO). (+)8-OH-
DPAT was dissolved in 0.85% NaCl (saline) at a concentration of 0.2mg/ml and administered at 
a dose of 0.2mg/kg s.c. Solutions were made fresh before injection. 
Rats were given unilateral intra-PVN injections of GPR30-mis-Ads as previously 
described [117]. Five days after injection, rats were treated with either estradiol (10ug/kg, 0.4 
ml/kg, sc) or sesame oil for 2 days. 20 hours after last injection, rats were treated with 8-OH-
DPAT (200ug/kg, sc) or saline and then were decapitated 15 min after the treatment. Brains were 
removed. The PVN was removed and stored at -80°C.   
PVN tissue was homogenized using 100ul homogenization buffer (50 mM Tris, pH 7.4, 
10 mM EGTA, 100 mM NaCl, 0.5% Triton X-100. 20mM NEM, 1/100 dilution of phosphatase 
inhibitors and protease inhibitors were added before use) using motorized homogenizer 
(Powergene 1000 with 5mm probe) at speed 5, 4
o
C for 10 sec or until all of the tissue was 
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homogenized. The homogenate was spun at 25,000xg (16,500 rpm) for 1 hr at 4
0
C. The 
supernatant was collected as the cytosol fraction. The membrane fraction was reconstituted with 
50 μl solubilization buffer described above for cell lysate. The following procedure for 
membrane fraction of PVN was the same as that for cell lysates.  
2.4. Immunoprecipitation (IP) 
Immunoprecipitation was conducted using 250ug protein of membrane fraction of N2a 
cells or hypothalamic region of rat brain, prepared as described above.  The sample was added to 
50 ul prewashed rprotein G agarose (Cat# 15920-010, Invitrogen, USA) in total volume of 250ul 
IP buffer (50 mM Tris, pH 7.4, 10 mM EGTA, 100 mM NaCl, 0.5% Triton X-100, containing 20 
mM N-ethymaleimide, 1X protease inhibitor cocktail, 1X phosphatase inhibitor cocktail I and II, 
respectively) and then was rotated at 4
o
C for 1h. After centrifugation at 10,000rpm at 4
o
C for 
10min, the supernatant was incubated with 2.5ug anti-SUMO1 antibody (Cat# sc-5308, Santa 
Cruz, USA) or mouse IgG control (Cat# sc-2025, Santa Cruz, USA) on a rotator at 4
o
C 
overnight. The solution were added to 100ul pre-washed beads and then rotated at 4
o
C for 2 
hours. The protein G beads-immune complex was centrifuged at 1000rpm for 3 minutes at 4
o
C. 
The pellet was washed with 0.5ml ice-cold IP buffer 3 times. After washing, the proteins were 
eluted from the immune complexes using 50ul 2X sample buffer with β-mercaptoethanol and 
incubated at 95
o
C for 5 min following by centrifugation at 12,000rpm for 5 min at room 
temperature. The eluate was stored in -80
o
C or was loaded onto 10% SDS-PAGE gels. 
2.5. Immunoblot assays 
Protein samples were resolved in the 10% SDS-PAGE and then transferred to 
polyvinylidene fluoride (PVDF) membranes. After transferring, the PVDF membranes were 
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incubated in 5% non-fat milk in Tris-buffered saline, pH 7.6, with 0.1% Tween-20. The 
membranes were incubated overnight with primary antibodies listed in Table 4. After washing 4 
times, the membranes were incubated with the appropriate following secondary antibodies listed 
in Table 4. 
Table 4. Antibodies used for immunoprecipitation and immunoblots 
Antibodies Dilution Source 
Rabbit anti-5-HT1A Receptors 1:1000 Cat# PA5-28090, Thermo Fisher, USA 
Rat-anti-Flag 1:2000 Cat# 200474-21, Agilent, USA 
Mouse-anti-Na+, K+, ATPase 1:1000 Cat# 05-369, Millipore, USA 
Rabbit-anti-PIAS 1 1:2000 Gift from Dr. Yoshiaki Azuma 
Rabbit-anti-PIASx alpha  1:2000 Gift from Dr. Yoshiaki Azuma 
Rabbit-anti-PIAS 3 1:2000 Gift from Dr. Yoshiaki Azuma 
Rabbit-anti-PIASy 1:2000 Gift from Dr. Yoshiaki Azuma[118] 
Mouse-anti-βactin  1:20000 Cat# 691001, MP Biomedicals, LLC 
Goat-Anti-Mouse IgG 1:10000 Cat# 119380, Jackson 
ImmunoResearch, USA 
Goat Anti-Rabbit IgG 1:10000 Cat# 120745, 
JacksonImmunoResearch, USA 
 
Immunodetection was performed using an ECL kit (Cat# WBLUR0500, Millipore, USA, 
Cat# 10026384, Cat# 10026385, BioRad, USA) and ImageLab 3.0 software (BioRad, Hercules, 
CA). To normalize the protein levels, the intensity of bands were first normalized to the mean 
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intensity of the bands of mock transfection samples following by normalized to its beta-actin 
band.  
2.5. Immunocytochemistry  
The N2a cells were plated on coverslips, which had been coated with 500ul poly-D-lysine 
and then put back into incubator.  After 30 min, the media containing the 50% Dulbecco's 
Modified Eagle Medium (1X DMEM, high glucose, pyruvate, Cat# 11995-073, Thermo Fisher, 
USA) and 50% Opti MEM ( Cat# 31985088, Thermo Fisher, USA) supplemented with  10% 
charcoal Fetal Bovine Serum (FBS) (Cat# S11150, Atlanta Biologicals, USA ) and 1% 
Penicillin-Streptomycin solution (Cat# P0781-100ML, Sigma, USA) was added into plates.  
After 16-24 hours, the cells were transfected with plasmid constructs of pcDNA4 HisMax 
C-5-HT1A R or pmCherry-C1- 5-HT1A R to the N2a cells using Lipofectamine 3000 (Cat# 
L3000015, Thermo Fisher, USA). Medium was changed 24 hours after transfection.  
48 hours after transfection, the cells were washed with 2ml cold phosphate-buffered saline, 
pH 7.4 (PBS) and then fixed and permeabilized with ice-cold methanol for 2 min in -20˚C. Next, 
the cells were washed with PBS and incubated with blocking buffer (10% Normal Goat Serum) 
at room temperature for 30 min. After washing, cells were then incubated overnight with the 
mouse-anti-Na+, K+, ATPase antibody (1:500) (Cat# 05-369, Millipore, USA) and rabbit anti-5-
HT1A R antibody (1:200) (Cat# PA5-28090, Thermo Fisher, USA) at 4°C. Next, cells were 
washed three times with PBS and incubated with Alexa Fluor 488 conjugated goat-anti-mouse 
(1:500) (Cat# A-11001, Thermo Fisher, USA) and Alexa Fluor 568 conjugated goat anti-rabbit 
(1:500) (Cat# A-11011, Thermo Fisher, USA) diluted in the blocking buffer for 2 hrs. Cells were 
then washed with PBS and then with autoclaved ddH2O. Finally, the cells were mounted onto 
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microscope slides using Prolong Gold antifade regent with DAPI. The slides were stored at 4˚C 
and imaged using a confocal microscope. 
2.6. Data analysis and statistics 
All data were analyzed by one-way or two-way analysis of variance (ANOVA) using a 
statistical program (GraphPad Prism, version 6.02) followed by post-hoc tests including 
Dunnett’s multiple comparisons test (only comparisons with one control) or Tukey’s multiple 















CHAPTER 3: RESULTS 
3.1. Overexpression of 5-HT1A Rs 
To determine whether the N2a cells express endogenous 5-HT1A Rs and can express 
exogenous 5-HT1A Rs constructs, we first transfected N2a cells with plasmid constructs of 
pcDNA4 HisMax C- 5-HT1A R. Immunolabeling was used to identify the endogenous expression 
and overexpression of 5-HT1A Rs.  Our results (Figure 1) show that there was an increase of 
expression level of 5-HT1A Rs in the cells transfected with pcDNA4 HisMax C- 5-HT1A R 
constructs, indicating that N2a cells can overexpress 5-HT1A Rs.  Furthermore, the overexpressed 
5-HT1A Rs are located not only in the plasma membrane, but also in the cytosol of N2a cells.  
3.2. Overexpression of SUMO machinery 
In order to investigate which PIAS proteins and SENPs are involved in the SUMOylation 
of 5-HT1A Rs, we transfected various Flag-PIAS and Flag-SENP constructs into N2a cells. The 
expression level of transfected PIAS and SENPs constructs was examined by immunoblotting 
with an anti-Flag antibody. In the whole cell lysate, among the various PIAS constructs 
transfected, the PIASy construct expressed most abundantly followed by the PIAS1 construct. 
The expression level of transfected PIAS3 construct is less abundant than PIAS1 construct. 
Transfected constructs PIASxα and PIASxβ expressed the least amount of proteins.  
Interestingly, PIASxβ expressed so little that in the whole lysate, PIASxβ can hardly be detected 
(Figure 2A). In the membrane fraction, the expression of transfected PIASy is the most 
abundant. The expression of transfected PIAS1 construct is much lower than PIASy but more 
than PIAS3 and PIASxα, which show similar expression levels. In contrast, the expression of 
PIASxβ is the lowest among the transfected PIAS constructs. Comparing the expression level of 
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each PIAS protein in the whole lysate and membrane indicates that the ratio of PIASxα and 
PIASxβ in the membrane compared to that in the whole lysate is higher than that of other PIAS 
proteins (Figure 2B), indicating that PIASxα and PIASxβ may traffic to membrane of cells and 
could be involved in the SUMOylation of membrane proteins such as 5-HT1A Rs. The expression 
level of endogenous and transfected PIAS proteins in the membrane fraction were also detected 
using specific anti-PIAS antibodies. Results showed that N2a cells express endogenous PIAS 
proteins but not robustly (Figure 2C). In the cells transfected with PIAS constructs, the total 
expression level of each PIAS protein in the membrane fraction of cells was also detected to 
verify the expression of transfected PIAS constructs (Figure 2C).  
We also examined the expression levels of SENP1, SENP2, SENP6 in N2a cells. 
Transfected constructs of SENP1, SENP2, SENP6 were expressed in a similar level in the whole 
lysate (Figure 2D). Altogether, these data indicates that N2a cells are a good model to express 
SUMO machinery. 
Na+, K+ ATPase, the plasma membrane marker was used to verify separation of 
membrane and cytosolic fractions (Figure 2E). The results show that there was abundant Na+, 
K+ ATPase in the membrane fraction while there was little in the cytosolic fraction, indicating 
successful separation of membrane and cytosol fraction.  
3.3. SUMOylation of 5-HT1A Rs and the role of different PIAS proteins in 
SUMOylation of 5-HT1A Rs 
 
Since we have already examined the expression level of SUMO machinery, we sought to 
examine if SUMO 1 protein can covalently bind with 5-HT1A Rs. N2a cells were co-transfected 
with constructs of pcDNA4 His MaxC-5-HT1A R and HA-SUMO 1. Cell lysates were 
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immunoprecipitated with mouse monoclonal anti-SUMO 1 antibody and immunoblotted with 
rabbit polyclonal anti-5-HT1A R antibody to detect the SUMO 1- 5-HT1A R complex. We 
observed bands around 55kDa (Figure 3A), which is the predicted molecular size for SUMO 1- 
5-HT1A R complex as previously detected in different regions of rat brain tissue. In addition, 
when an irreversible cysteine peptidase inhibitor that inhibits sentrin/SUMO-specific proteases 
(SENPs), the protease responsible for deSUMOylation of proteins i.e. N-ethylmaleimide (NEM) 
was not used to harvest N2a cells and conduct immunoprecipitation experiments, the intensity of 
SUMOylated 5-HT1A Rs was dramatically decreased, thus confirming that the band around 55 
kDa represents the SUMOylated 5-HT1A Rs. 
Next, we examined the effect of different PIAS proteins on the SUMOylation of 5-
HT1A Rs. N2a cells were co-transfected with pcDNA4 His MaxC-5-HT1A R and HA-SUMO 1 
with or without different constructs expressing PIAS proteins. SUMO 1-5-HT1A Rs were 
immunoprecipitated with mouse monoclonal anti-SUMO 1 antibody and incubated with rabbit 
polyclonal anti-5-HT1A R antibody. One-way ANOVA shows that there is significant effect of 
transfection (F (5, 12) = 4.612, p = 0.0140). Dunnett’s multiple comparisons post-hoc test shows 
that PIASxα significantly increased the SUMOylated 5-HT1A Rs compared to the cells 
transfected with 5-HT1A Rs and SUMO 1 (Figure 3B). PIAS1, PIAS3 and PIASy constructs 
overexpressed abundantly, but did not significantly alter SUMOylation of 5-HT1A Rs. PIASxβ 
expressed the least and there was no significant effect on SUMOylation of 5-HT1A Rs.  
Considering the difference in expression of different PIAS constructs, especially PIASxβ, 
more PIASxβ construct was transfected to N2a cells in order to obtain higher levels of protein 
expression. However, the expression level of PIASxβ did not increase much (Figure 3C). 
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Interestingly, when N2a cells were just transfected with PIASxβ constructs, there was a 
significant decrease on the SUMO1-5-HT1A Rs compared to mock transfected cells (Figure 3D).  
3.4. The effect of treatment of EB and 8-OH-DPAT on the PIAS proteins in the PVN 
Previous experiments in our laboratory demonstrated that acute treatment with 8-OH-
DPAT, a 5-HT1A R agonist for 15 min increased the level of SUMO1-5-HT1A Rs in the 
hypothalamic membrane. In addition, treatment with EB for 2 days followed by acute treatment 
with 8-OH-DPAT for 15 min further enhanced the level of SUMO1-5-HT1A Rs. In order to 
understand the mechanisms underlying the effect of treatment on SUMOylation of 5-HT1A Rs, I 
examined the expression level of different PIAS proteins in the membrane fraction of the PVN of 
rats following identical treatment with 8-OH-DPAT and EB. Specific anti-PIAS1, anti-PIASxα, 
anti-PIAS3 and anti-PIAS4 antibodies were used to detect the expression level of corresponding 
PIAS protein. 
For PIAS1, two bands around its predicted molecular weight were observed using 
immunoblotting (Figure 4A). Since the right band for PIAS1 cannot be identified among these 
two bands, both the two bands were measured to quantify the effect of treatments on the 
expression of PIAS1. Two-way ANOVA shows there was no significant effect of pretreatment, 
treatment and interaction on the expression level of PIAS1 (Upper bands: Two-way ANOVA: 
main effect of pretreatment (EB): F(1,8)=3.041, p=0.1193; main effect of treatment (8-OH-DPAT): 
F(1,8)=0.006659, p=0.9370; interaction between pre-treatment and treatment: F(1,8)=0.01447, 
p=0.9072; Lower bands: Two-way ANOVA: main effect of pretreatment (EB): F(1,8)=3.551, 
p=0.0963; main effect of treatment (8-OH-DPAT): F(1,8)=1.498, p=0.2558; interaction between 
pre-treatment and treatment: F(1,8)=0.2503, p=0.6303). 
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For the PIASxα expression level, two-way ANOVA showed that there was significant 
effect of EB treatment but no significant effect of 8-OH-DPAT treatment or the interaction 
between EB and 8-OH-DPAT. Tukey’s multiple comparisons post-hoc test shows that the 
expression of PIASxα was unchanged with the activation of 5-HT1A Rs by acute treatment with 
8-OH-DPAT alone compared to the vehicle treatment (Figure 4B). In addition, treatment with 
EB alone also had no significant effect on the PIASxα expression level in comparison to vehicle 
treated rats. Moreover, there was no alteration of the expression level of PIASxα when combined 
treatment of EB and 8-OH-DPAT is compared to treatment of EB alone. However, rats treated 
with EB followed by 8-OH-DPAT showed a significant increase in the PIASxα level in the rat 
PVN membrane fraction by about 40% compared to the 8-OH-DPAT-treated rats. (Two-way 
ANOVA: main effect of pre-treatment (EB): F(1,8)= 7.446, p=0.0259; main effect of treatment (8-
OH-DPAT): F(1,8) =3.822, p=0.0863; interaction between pre-treatment and treatment: F(1,8) = 
4.086, p=0.0779). 
With respect to PIAS3, two-way ANOVA analysis showed that there was no significant 
effect of pre-treatment, treatment and interaction on the expression level of PIAS3 (Two-way 
ANOVA: main effect of pre-treatment(EB): F(1, 8) =0.02531, p=0.8775 ; main effect of treatment 
(8-OH-DPAT): F(1,8)=0.006120, p=0.9396; interaction between pre-treatment and treatment: 
F(1,8)= 0.009228, p=0.9258) 
In terms of expression level of PIASy, two-way ANOVA showed there was significant 
effect of EB treatment but not 8-OH-DPAT treatment or interaction between EB and 8-OH-
DPAT treatment. Tukey’s multiple comparisons post hoc test shows that the expression level of 
PIASy was increased significantly in the rats treated with EB alone compared to vehicle treated 
rats. However, no effect on PIASy expression was seen in 8-OH-DPAT-treated group compared 
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to vehicle treated rats or the rats treated with EB and 8-OH-DPAT together. Intriguingly, there 
was no significant change between EB treated rats and rats co-treated with EB and 8-OH-DPAT. 
(Two-way ANOVA: main effect of pre-treatment(EB): F(1,8)=8.463, p=0.0196; main effect of 
treatment (8-OH-DPAT): F(1,8)=0.1524, p=0.7064; interaction between pre-treatment and 
treatment: F(1,8)=3.760, p=0.0885).  
 
Figure 1. Overexpression of 5-HT1A Rs 
Figure 1. Overexpression of 5-HT1A Rs. The N2a cells were transfected with plasmid construct 
of pcDNA4 His MaxC-5-HT1A R. 48 hrs after transfection, the cells were fixed in methanol. 
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Figure 2. The expression of PIAS proteins in N2a cells. 
38 
 
Figure 2. The expression of PIAS proteins in N2a cells.  N2a cells were transfected with Flag-
tagged PIAS plasmid constructs. The whole cell lysates (A) and the membrane fraction of cells 
(B) were resolved on 10% SDS-PAGE gels, proteins were transferred to PDVF membranes and 
the blot was incubated with anti-flag antibody. (C) The expression of each PIAS protein in the 
membrane fraction was detected using specific anti-PIAS antibodies. (D) The expression of 














Figure 3. The role of PIAS proteins in the SUMOylation of 5-HT1A Rs. 
Figure 3. The role of PIAS proteins in the SUMOylation of 5-HT1A Rs. The N2a cells were 
transfected with pcDNA4 His MaxC-5-HT1A R, HA-SUMO 1 and various plasmid constructs of 
PIAS as indicated in the figures. Membrane fractions were isolated 48 hours after transfection. 
The SUMOylated 5-HT1A Rs were immunoprecipitated using a mouse anti-SUMO 1 antibody 
and immunoblotted using a rabbit anti-5-HT1A Rs antibody.  (A) 5-HT1A Rs were SUMOylated 
by SUMO1 in N2a cells. IgG: immunoprecipitation with the same amount of mouse IgG instead 
of a mouse anti-SUMO1 antibody. MT: Mock transfected, cells were transfected with empty 
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vector. Various amounts of empty vector were added to get the same amount of plasmid 
constructs in total per dish. (B) The effect of PIAS proteins on SUMOylation of 5-HT1A Rs. Data 
are presented as mean ± SEM (n=3). * One-way ANOVA shows there is significant effect of 
transfection of PIAS on SUMOylation of 5-HT 1ARs (F (5, 12) = 4.612, P = 0.0140). Dunnett’s 
multiple comparisons post-hoc test shows that SUMOylation of 5-HT1A R significantly 
increased in the group transfected with pcDNA4 His MaxC-5-HT1A R, HA-SUMO 1 and  
PIASxα compared to the group transfected with the pcDNA4 His MaxC-5-HT1A R and HA-
SUMO 1 (p<0.05). (C) N2a cells were transfected with 1.5 µg empty vector (MT), 1.5 µg, 7.5 
µg and 15µg plasmid construct of Flag-PIASxβ respectively. The expression level of PIASxβ 
was detected using anti-Flag antibody. (D) N2a cells were transfected with same amount of 
empty vector and construct of PIASxβ. SUMO1-5-HT1A Rs were immunoprecipitated by anti-
SUMO1 antibody and detected by anti-5-HT1A R antibody. *** unpaired t test shows there is 
significant difference between mock transfected group and PIASxβ transfected group, p=0.0002) 










Figure 4. The effect of EB and 8-OH-DPAT on the PIAS proteins in the rat PVN. 
Figure 4. The effect of EB and 8-OH-DPAT on the PIAS proteins in the rat PVN.  Rats were 
given unilateral intra-PVN injections of GPR30-mis-Ads. 5 days after injection, Rats were 
treated with either estradiol (10ug/kg, 0.4 ml/kg, s.c) or oil for 2 days. 20 hours after the last 
injection, rats were treated with 8-OH-DPAT (200ug/kg, s.c) or saline and then were decapitated 
15 min after the treatment.  (A), (C) The effect of EB and 8-OH-DPAT on the PIAS1 and PIAS3 
respectively. (B) The effect of EB and 8-OH-DPAT on PIASxα.  * Two-way ANOVA shows 
there is significant effect of EB on the expression of PIASxα.  Post hoc by Tukey’s multiple 
comparisons test shows that treatment of EB and 8-OH-DPAT together induced PIASxα to 
significantly increase in rats PVN membrane fraction compared to the group treated with 8-OH-
DPAT alone (p<0.05). (D) The effect of EB and 8-OH-DPAT on PIASy.  * Two-way ANOVA 
shows there is significant effect of EB on the expression of PIASy.  Post hoc by Tukey’s 
multiple comparisons test shows that PIASy was increased significantly in the group treated with 












CHAPTER 4: DISCUSSION 
 
Previous studies have reported SUMOylation of 5-HT1A Rs by SUMO 1 in rat brain areas 
such as hypothalamus, hippocampus and cortex. However, the mechanisms regulating 
SUMOylation of 5-HT1A Rs were not elucidated. In this study, we focused on the mechanisms 
underlying the SUMOylation of 5-HT1A Rs by SUMO1. Our studies have demonstrated for the 
first time that 1)  N2a cells express endogenous SUMO machinery and SUMOylation machinery 
can be over-expressed in N2a cells via transfection. 2) The SUMOylation of 5-HT1A Rs was 
detected around 55 kDa in N2a cells similar to that seen in the rat brain. 3) The PIAS proteins 
were found to be distributed in the membrane fraction of N2a cells, although previous stuides 
reported to their location only in the nucleus and cytosol of cells. 4) Although transfected 
PIASxα construct was expressed at low levels in the whole lysate, a higher proportion of PIASxα 
was expressed in the cell membrane fraction as compared to the cytosolic fraction, suggesting 
that PIASxα is positioned to participate in the SUMOylation of 5-HT1A Rs. 5) Even though the 
expression level of transfected PIASxα was low, PIASxα facilitated the covalent conjugation 
between SUMO 1 and 5-HT1A Rs.  Although there was a much higher amount of PIAS1 and 
PIASy proteins in the whole lysate preparation as well as the membrane fraction of N2a cells 
after transfection, PIAS1 and PIASy did not affect SUMOylation of 5-HT1A Rs. 6) The 
expression level of PIASxα in the membrane fraction of rat PVN is increased significantly by 
treatment with EB and 8-OH-DPAT compared to the rats treated with 8-OH-DPAT alone. EB 
treatment alone increase PIASy level in the membrane fraction of rat PVN in comparison to 
vehicle treated rats. 
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In the current study, we used N2a cell line, a mouse neuroblastoma cell line, which I 
found endogenously expresses 5-HT1A Rs. The predicted molecular weight of 5-HT1A Rs is 
around 42kDa. However anti-5-HT1A R antibody detected bands of very strong intensity at 
55kDa. Initial experiments conducted by our laboratory using rat brain tissue found that the anti-
5-HT1A R antibody detected several protein bands including a ~75kDa, 55kDa and other small 
bands but not a 42 kDa. The highest intensity band detected by the 5-HT1A R antibody was the 
55kDa band, which was verified as SUMO1-5-HT1A Rs band later using immunoprecipitation. 
These results suggest that monoSUMOylation of 5-HT1A Rs is an abundant post-translational 
modification (PTM) in rat brain tissue. Our laboratory also showed that in the HEK 293 cells, 
bands around 42 kDa and 55 kDa were detected. This different pattern of 5-HT1A Rs in the rat 
brain tissue suggests that there are differences in PTM of 5-HT1A Rs between brain tissue and 
cell lines. However, the bands for 5-HT1A Rs in N2a cells are similar to what we observed in the 
rat brain tissue indicating that N2a cells mimic the SUMOylated 5-HT1A Rs identified in rat 
brain. Thus, N2a cells are a better model to study the SUMOylation of 5-HT1A Rs.  
Once we established the cell model, we looked at the distribution of PIAS proteins in N2a 
cells. Studies have shown that SUMO machinery traffics to different regions of neurons during 
the neuronal development [84, 85]. Our laboratory has previously reported that  SUMO1-5-HT1A 
Rs are distributed in the ER and Golgi, while a small proportion of SUMO1-5-HT1A Rs are 
located in DRM where the active 5-HT1A Rs are located. Based on this background, we 
hypothesized that PIAS proteins facilitate SUMOylation of 5-HT1A Rs in N2a cells by 
distributing in the plasma membrane (Figure 5).  
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Figure 5. The schematic representation of mechanisms underlying the SUMOylation of 5-
HT1A Rs in N2a cells. The PIAS protein might need to be located to the plasma membrane to 
accelerate the transfer of SUMO 1 protein to 5-HT1A Rs. 
In the present study, cells were transfected with PIAS constructs and PIAS proteins were 
found to be expressed in the membrane fraction of N2a cells. However, previous studies reported 
that the PIAS proteins are located in the cytosol and nucleus. The disparity between the 
distribution of PIAS proteins might be because of the differences in cell lines or tissues. 
Moreover, the distribution of PIAS proteins in the membrane fraction of N2a cells is consistent 
with our hypothesis that PIAS proteins increase SUMOylation of 5-HT1A Rs in the plasma 
membrane. However, in my experiment, I used sodium cholate to extract the hydrophobic 
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proteins located in the plasma membrane including DRM as well as Golgi and ER. In order to 
study the distribution of PIAS proteins and SUMO1-5-HT1A Rs and to examine whether they co-
localize, separation of different sub-cellular fractions of N2a cells by ultracentrifugation or 
immunocytochemistry needs to be done.  
There was a surprisingly large difference in the expression of PIAS proteins in whole 
lysates and the membrane fraction of N2a cells following transfection. This apparent difference 
between the expression levels of each transfected PIAS constructs appeared even though the 
contructs have the same vector backbone. The difference in expression level of transfected PIAS 
in the plasma membrane may be associated to the selectivity of each PIAS protein to different 
substrates. Interestingly, the PIASxβ construct expressed the least among the PIAS constructs 
and transfection of higher amounts of PIASxβ still resulted in lower expression of PIASxβ. 
Transfection with PIASxβ alone led to a decrease in SUMOylation of 5-HT1A Rs compared to 
the mock transfected cells. In contrast, transfection of PIASxβ together with constructs of 5-
HT1A R and SUMO 1 showed no significant effect on the SUMOylation of 5-HT1A Rs. These 
results suggest that PIASxβ may require more 5-HT1A Rs, SUMO and Ubc9 to be involved in the 
SUMOylation of 5-HT1A Rs. 
I also examined SUMOylation of 5-HT1A Rs by transfection of various SUMO-1 and 5-
HT1A R constructs during initial studies of the N2a cells as a cell model. pmchcerry-C1-5-HT1A 
R, pAcGFP- C1-5-HT1A R, pmchcerry-C1-SUMO1 and pAcGFP-SUMO1 constructs were 
transfected into N2a cells and immunoprecipitation was conducted using anti-SUMO antibody. 
However, the appropriate molecular weight protein bands were not observed (data not shown). It 
is likely that the mcherry tag and GFP tag which are around 28 kDa, interferes with the binding 
or trafficking of SUMO machinery for 5-HT1A Rs. 
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In the N2a cell model, it was found that PIASxα was able to enhance the covalent 
conjugation between SUMO1 and 5-HT1A Rs, which leads to the question if there is an increase 
in PIASxα expression when the SUMOylation of 5-HT1A Rs increased. In our current 
experiments, we found that combination of EB and 8-OH-DPAT significantly increased the 
expression levels of PIASxα in PVN membrane fraction compared to rats treated with 8-OH-
DPAT alone. Previous studies in our laboratory showed that co-treatment of EB and 8-OH-
DPAT significantly up-regulated the SUMOylation of 5-HT1A Rs in the hypothalamic membrane 
compared to the rats treated with 8-OH-DPAT alone. Taken together, these previous and current 
results suggest that combined treatment of EB and 8-OH-DPAT facilitate SUMOylation of 5-
HT1A Rs via increasing PIASxα in the PVN membrane. Further experiments to determine the 
expression level of PIASxα in the whole homogenate of PVN need to be conducted to identify 
whether the total expression level of PIASxα was increased or whether PIASxα traffics from 
cytosol to membrane to participate in the SUMOylation of 5-HT1A Rs.  
In the present study, administration of EB alone did not have significant effect on the 
expression level of PIASxα in comparison to vehicle treatment, indicating that EB alone cannot 
increase the expression level of PIASxα, which is consistent to our previous finding that 
treatment of EB alone did not increase SUMOylation of 5-HT1A Rs. 
The unchanged expression level of PIASxα in the PVN membrane fraction by acute 
treatment of 8-OH-DPAT compared to vehicle treated rats was observed in the present study, 
indicating that 8-OH-DPAT alone did not alter the expression level of PIASxα. However, 
previous studies in our laboratory demonstrated that 8-OH-DPAT alone increased the level of 
SUMO1-5-HT1A Rs in the hypothalamic membrane and DRM. The reason why 8-OH-DPAT did 
not increase PIASxα might be explained by the different tissue fractions used. In the 
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hypothalamus, 5-HT1A Rs are not only located in PVN of hypothalamus, but also in  other parts 
of hypothalamus, such as dorsomedial hypothalamus (DMH) [116, 119]. 8-OH-DPAT might 
regulate the SUMOylation of 5-HT1A Rs in other parts of hypothalamus. It is also likely that 
treatment of 8-OH-DPAT increases SUMOylation of 5-HT1A Rs through other mechanisms, e.g. 
the increased activity of PIASxα, increased activity or expression level of other E3 ligases, the 
decreased activity or expression of SENPs by the acute treatment of 8-OH-DPAT. Further 
experiments are needed to be done to examine the activity or expression of these enzymes after 
administration of 8-OH-DPAT.  
In the membrane fraction of rat PVN, it was found that treatment of EB alone 
significantly increased the expression level of PIASy , indicating that PIASy may be involved in 
EB-induced SUMOylation of other proteins like RGSz1 [120]. It was reported that RGSz1 can 
be SUMOylated and isoforms of SUMOylated- RGSz1 were around 35 kDa, 45kDa, 50kDa, 90 
kDa and 135kDa in the rat cortex. EB treatment increased the putative SUMOylated 135-kDa 
RGSz1 in PVN membrane fraction while 8-OH-DPAT had no effect on the putative 
SUMOylated 135-kDa RGSz1. Gαz, which couples to 5-HT1A Rs in hypothalamus, was also 
identified to be modulated by treatment with EB and to be the substrate of SUMO proteins [29]. 
However, previous study in our laboratory demonstrated that acute treatment with 8-OH-DPAT 
significantly increased SUMOylated-Gαz while treatment with EB alone for 2 days significantly 
decreased SUMOylated-Gαz, which suggests that PIASy is not likely involved in SUMOylation 
of Gαz. Interestingly, there is no effect for combined treatment of EB and 8-OH-DPAT on the 
expression level of PIASy in comparison to rats treated with 8-OH-DPAT alone, indicating 8-




To date, they are only four GPCRs including mGluR8b, mGluR7, CB1 and 5-HT1A Rs are 
identified as the substrates of SUMO proteins [35, 110-114]. Choi et al.,[113] found that 
SUMOylation stabilizes mGluR7 on the neuronal surface. DeSUMOylation of mGluR7 by L-
AP4, an mGluR7 agonist leads to a profound increase in the internalization of mGluR7 
indicating that deSUMOylation enhances endocytosis of mGluR7. Our laboratory demonstrated 
that acute treatment of 8-OH-DPAT promoted the SUMOylation of 5-HT1A Rs and majority of 
SUMO 1-5-HT1A Rs   are located in the ER and Golgi. Further experiments need to be done to 
detect the trafficking of SUMO 1-5-HT1A Rs, PIAS proteins and deSUMOylation proteases, 
which could provide a deeper insight into the mechanisms involved in regulation of 5-HT1A Rs. 
My experiments found that PIASxα facilitates the SUMOylation of 5-HT1A Rs, which 
could become a target for regulation of 5-HT1A Rs. In the future, PIASxα can be knocked down 
in N2a cells or animal model to verify that PIASxα involves in increasing SUMOylation of 5-
HT1A Rs. In addition, experiments will be conducted to identify the binding site of PIASxα on 5-
HT1A Rs and the binding site of SUMO1 on 5-HT1A Rs. Further, the function of deSUMOylation 
proteases such as SENPs leading to the significant deSUMOylation of 5-HT1A receptors should 
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